Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Molecular therapy : the journal of the American Society of Gene Therapy - 1 Jan 2014

Workenhe Samuel T, Simmons Graydon, Pol Jonathan G, Lichty Brian D, Halford William P, Mossman Karen L

Abstract excerpt

Within the oncolytic virus field, the extent of virus replication that is essential for immune stimulation to control tumor growth remains unresolved. Using infected cell protein 0 (ICP0)-defective oncolytic Herpes simplex virus type 1 (HSV-1) and HSV-2 viruses (dICP0 and dNLS) that show differences in their in vitro replication and cytotoxicity, we investigated the inherent features of oncolytic HSV viruses that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen-Presenting Cells
Share to Cytopathogenic Effect, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Herpesvirus 1, Human

Share to Herpesvirus 2, Human

Share to HMGB1 Protein

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Simplexvirus

Source

Open in PubMed Open full text

Identifiers

PMID: 24343053
DOI: 10.1038/mt.2013.238
PMCID: PMC3978812

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.PMID 24343053Read ↗

The oncolytic virus ΔPK has multimodal anti-tumor activity.Semantic proximity Read ↗

Evolution of Oncolytic Viruses: Novel Strategies for Cancer TreatmentSemantic proximity Read ↗

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapySemantic proximity Read ↗

Oncolytic virotherapy: the questions and the promiseSemantic proximity Read ↗

Oncolytic virotherapy for cancer treatment: challenges and solutionsSemantic proximity Read ↗

Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic VirotherapySemantic proximity Read ↗

Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1Semantic proximity Read ↗

A modified oncolytic measles virus exhibits strong immunotherapeutic potential through RIG-I activation by defective viral genomesSemantic proximity Read ↗

The Antiviral and Antitumor Effects of Defective Interfering Particles/Genomes and Their MechanismsSemantic proximity Read ↗

Oncolytic viruses: finally deliveringSemantic proximity Read ↗

A novel oncolytic HSV-1 vector for cancer immunotherapySemantic proximity Read ↗

Memory versus effector immune responses in oncolytic virotherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.